arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ADC Therapeutics SA

ADCT
$1.65 ▼ -0.07 (-4.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Neutral
auto_awesome

Analytical Summary

ADC Therapeutics SA shows mixed fundamentals. On the positive side, Return on Common Equity (%) remains strong. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $255.8M
Dividend Yield —
Revenue Growth 2.2% ↗
Op. Margin -132.0% ↘
ROIC 11.1% ↘
FCF / Share $-0.08 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.25M
↑ +2.2% —
Net Income Profit after all expenses
$-16.57M
↑ +70.8% —
Operating Margin Operating profit as % of sales
-132.0%
↓ -9.1% 1th
FCF / Share Free cash flow per share
$-0.08
↑ +60.5% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
98
Financial Health ↓
33
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 18 quarters